Pharmaceutical Technology on MSN
MSD pays up to nearly $600m for Evaxion’s mystery vaccine candidate
Evaxion’s preclinical asset targets an unknown infectious disease in which there are no other vaccines available.
MS Emerging Markets Debt is a fixed income closed end fund. The vehicle focuses on emerging markets, more specifically on hard currency EM debt. The CEF is now trading with a -14% discount to net ...
InvestorsHub on MSN
Evaxion Biotech Shares Jump Following MSD Vaccine Licensing Deal
Evaxion Biotech AS (NASDAQ:EVAX) surged 33% in premarket trading Thursday after announcing that MSD (NYSE:MRK) has exercised its option to license Evaxion’s vaccine candidate EVX-B3. Under the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback